Each dot is one of the 94 Pharmaceuticals and Biotechnology stocks, sized by market cap. The median Revenue Growth (1y) (TTM) is 13.3% and the median P/E 18.89. Pinned to the edge: 11 outliers on X and 5 on Y.
Quadrants split at the medians. Hover a dot for its true values; click to open the company. Outliers are more than 3× the interquartile range beyond the quartiles.
| # | Industry | ||||
|---|---|---|---|---|---|
| 1 | LLYEli Lilly | 49.6% | 42.74 | $1.14T | Pharmaceuticals |
| 2 | JNJJohnson & Johnson | 7.8% | 39.74 | $639.60B | Pharmaceuticals |
| 3 | ABBVAbbVie | 10.4% | 79.99 | $504.75B | Pharmaceuticals |
| 4 | MRKMerck | 4.6% | 109.51 | $347.48B | Pharmaceuticals |
| 5 | NVSNovartis Ag | 2.8% | 18.87 | $297.75B | Pharmaceuticals |
| 6 | AZNAstrazeneca | 9.4% | 25.33 | $264.65B | Pharmaceuticals |
| 7 | AMGNAmgen | 9.1% | 27.26 | $238.35B | Biotechnology |
| 8 | ABTAbbott Laboratories | 8.1% | 33.40 | $181.19B | Medical Devices |
| 9 | PFEPfizer | -0.2% | 39.13 | $169.52B | Pharmaceuticals |
| 10 | VRTXVertex Pharmaceuticals | 10.2% | 29.51 | $130.02B | Biotechnology |
| 11 | BMYBristol Myers Squibb | 3.1% | 13.46 | $124.97B | Pharmaceuticals |
| 12 | GSKGsk | 87.0% | 7.81 | $103.38B | Pharmaceuticals |
| 13 | REGNRegeneron Pharmaceuticals | 9.3% | 19.01 | $82.30B | Biotechnology |
| 14 | TAKTakeda Pharmaceutical | 0.7% | 111.79 | $64.20B | Pharmaceuticals |
| 15 | CORCencora | 5.1% | 24.27 | $63.71B | Drug Distribution |
| 16 | ARGXArgenx Se | 61.5% | 28.34 | $53.20B | Biotechnology |
| 17 | SNYSanofi | 27.7% | 10.91 | $50.84B | Pharmaceuticals |
| 18 | TEVATeva Pharmaceutical Industries | 4.1% | 65.62 | $46.33B | Generic Drugs |
| 19 | IDXXIdexx Laboratories | 12.8% | 39.43 | $44.93B | Animal Health |
| 20 | ONCBeOne Medicines | 34.3% | 63.10 | $41.38B | Pharmaceuticals |
| 21 | BIIBBiogen | 0.3% | 44.30 | $36.97B | Biotechnology |
| 22 | ALCAlcon | 8.5% | 53.55 | $34.44B | Medical Devices |
| 23 | ZTSZoetis | 1.5% | 12.87 | $33.67B | Animal Health |
| 24 | GEHCGE HealthCare Technologies | 6.5% | 16.41 | $32.58B | Diagnostic Equipment |
| 25 | ALNYAlnylam Pharmaceuticals | 90.1% | 41.23 | $30.23B | Biotechnology |
| 26 | UTHRUnited Therapeutics | 2.5% | 19.08 | $25.02B | Pharmaceuticals |
| 27 | INCYIncyte | 26.9% | 14.04 | $22.63B | Pharmaceuticals |
| 28 | ZBHZimmer Biomet Holdings | 8.6% | 23.04 | $18.59B | Medical Devices |
| 29 | EXELExelixis | 9.2% | 18.91 | $16.27B | Pharmaceuticals |
| 30 | HALOHalozyme Therapeutics | 41.2% | 35.85 | $14.83B | Biotechnology |
| 31 | ASNDAscendis Pharma A | 128.4%OUT | 17.10 | $14.83B | Biotechnology |
| 32 | NBIXNeurocrine Biosciences | 34.4% | 20.73 | $14.62B | Pharmaceuticals |
| 33 | FMSFresenius Medical Care AG | -47.8% | 12.12 | $13.25B | Healthcare Services |
| 34 | JAZZJazz Pharmaceuticals | 12.6% | 13.81 | $13.00B | Pharmaceuticals |
| 35 | BWXTBWX Technologies | 22.7% | 33.58 | $11.93B | Nuclear Equipment |
| 36 | RDYDr Reddys Laboratories | -10.5% | 31.39 | $11.41B | Generic Drugs |
| 37 | GMEDGlobus Medical | 19.7% | 20.49 | $10.97B | Medical Devices |
| 38 | BMRNBiomarin Pharmaceutical | 11.2% | 147.67OUT | $10.78B | Biotechnology |
| 39 | PTGXProtagonist Therapeutics | 34.8% | 110.86 | $9.19B | Biotechnology |
| 40 | KRYSKrystal Biotech | 22.6% | 37.87 | $9.14B | Gene and Cell Therapy |
| 41 | CORTCorcept Therapeutics | 16.0% | 167.43OUT | $9.08B | Pharmaceuticals |
| 42 | CHWYChewy | 5.9% | 32.09 | $8.78B | Packaged Foods |
| 43 | TGTXTg Therapeutics | 76.1% | 17.35 | $7.66B | Biotechnology |
| 44 | ALKSAlkermes | 10.8% | 111.51 | $7.37B | Pharmaceuticals |
| 45 | AMRXAmneal Pharmaceuticals | 9.3% | 42.52 | $6.69B | Generic Drugs |
| 46 | LGNDLigand Pharmaceuticals | 54.9% | 30.93 | $6.10B | Biotechnology |
| 47 | KNSAKiniksa Pharmaceuticals International | 58.9% | 68.75 | $5.54B | Biotechnology |
| 48 | ARQTArcutis Biotherapeutics | 76.1% | 144.17OUT | $4.11B | Biotechnology |
| 49 | INDVIndivior Pharmaceuticals | 13.5% | 11.54 | $4.10B | Pharmaceuticals |
| 50 | LQDALiquidia | 2,234%OUT | 28.45 | $3.94B | Pharmaceuticals |
| 51 | OGNOrganon | -2.5% | 17.28 | $3.61B | Pharmaceuticals |
| 52 | ACADAcadia Pharmaceuticals | 11.8% | 8.84 | $3.36B | Pharmaceuticals |
| 53 | GMABGenmab A | 23.6% | 3.26 | $2.88B | Biotechnology |
| 54 | NRIXNurix Therapeutics | 738.8%OUT | 9.60 | $2.83B | Biotechnology |
| 55 | ADMAAdma Biologics | 8.0% | 14.81 | $2.50B | Biotechnology |
| 56 | VCELVericel | 23.0% | 91.03 | $2.20B | Gene and Cell Therapy |
| 57 | AUPHAurinia Pharmaceuticals | 19.8% | 7.02 | $2.20B | Pharmaceuticals |
| 58 | HRMYHarmony Biosciences Holdings | 24.3% | 11.64 | $2.11B | Pharmaceuticals |
| 59 | LKFTLakefront Biotherapeutics | 179.7%OUT | 3.01 | $2.09B | Biotechnology |
| 60 | PAHCPhibro Animal Health | 17.1% | 15.89 | $1.58B | Animal Health |
| 61 | INVAInnoviva | 18.8% | 4.29 | $1.53B | Pharmaceuticals |
| 62 | ANIPAni Pharmaceuticals | 30.9% | 14.13 | $1.53B | Generic Drugs |
| 63 | PCRXPacira BioSciences | 5.7% | 98.09 | $1.44B | Pharmaceuticals |
| 64 | ETONEton Pharmaceuticals | 72.3% | 163.80OUT | $1.40B | Pharmaceuticals |
| 65 | OMEROmeros | 1,532%OUT | 9.51 | $1.19B | Biotechnology |
| 66 | AMPHAmphastar Pharmaceuticals | 1.0% | 14.08 | $1.11B | Generic Drugs |
| 67 | RIGLRigel Pharmaceuticals | 3.3% | 2.86 | $919.82M | Biotechnology |
| 68 | TBPHTheravance Biopharma | 35.1% | 16.35 | $883.70M | Biotechnology |
| 69 | MGTXMeiraGTx Holdings | 957.3%OUT | 9.65 | $834.65M | Gene and Cell Therapy |
| 70 | ABUSArbutus Biopharma | 1,079%OUT | 5.43 | $831.35M | Biotechnology |
| 71 | PHARPharming | 1.9% | 43.32 | $816.89M | Biotechnology |
| 72 | COLLCollegium Pharmaceutical | 14.3% | 15.62 | $748.55M | Pharmaceuticals |
| 73 | CRMDCorMedix | 208.3%OUT | 3.72 | $620.49M | Pharmaceuticals |
| 74 | IRWDIronwood Pharmaceuticals | 26.2% | 4.38 | $568.84M | Biotechnology |
| 75 | ZVRAZevra Therapeutics | 119.6% | 9.60 | $559.62M | Pharmaceuticals |
| 76 | PBYIPuma Biotechnology | -2.9% | 20.65 | $550.15M | Biotechnology |
| 77 | DCTHDelcath Systems | 35.8% | 976.23OUT | $519.36M | Medical Devices |
| 78 | ARVNArvinas | -15.0% | 50.38 | $468.50M | Biotechnology |
| 79 | KMDAKamada | 13.2% | 20.64 | $455.98M | Biotechnology |
| 80 | ELTPElite Pharmaceuticals | 33.7% | 4.56 | $258.64M | Generic Drugs |
| 81 | AGENAgenus | 30.5% | 2.81 | $257.95M | Biotechnology |
| 82 | PLXProtalix BioTherapeutics | 30.1% | 10.51 | $199.17M | Biotechnology |
| 83 | CGENCompugen | 234.2%OUT | 5.02 | $176.57M | Biotechnology |
| 84 | QTTBQ32 Bio | 294.2%OUT | 42.88 | $171.28M | Biotechnology |
| 85 | VXRTVaxart | 201.1%OUT | 2.54 | $98.08M | Biotechnology |
| 86 | RLYBRallybio | -15.1% | 2.07 | $94.18M | Biotechnology |
| 87 | SPROSpero Therapeutics | -3.3% | 8.31 | $61.45M | Biotechnology |
| 88 | FBIOFortress Biotech | 16.1% | 7.10 | $59.29M | Biotechnology |
| 89 | ELUTElutia | -0.3% | 0.78 | $35.91M | Medical Devices |
| 90 | UGUnited Guardian | 3.2% | 12.36 | $30.48M | Pharmaceuticals |
| 91 | ETSTEarth Science Tech | 8.0% | 6.71 | $25.88M | Generic Drugs |
| 92 | CSCIFCOSCIENS Biopharma | -11.6% | 4.76 | $19.31M | Specialty Chemicals |
| 93 | KYNBKyntra Bio | 3.0% | 0.10 | $18.16M | Biotechnology |
| 94 | PTIXProtagenic Therapeutics, Inc.\new | -34.5% | 0.24 | $1.30M | Biotechnology |
Among Pharmaceuticals and Biotechnology stocks, the largest companies growing revenue faster than the median (13.3%) while trading below the median P/E (18.89) are Gsk (GSK), Sanofi (SNY), Incyte (INCY), Ascendis Pharma A (ASND) and Tg Therapeutics (TGTX). A low multiple next to fast growth can be an opportunity or a sign the market doubts the growth will last.
The largest companies with a P/E above the median and revenue growth below it are Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), Astrazeneca (AZN) and Amgen (AMGN).
The median P/E across the 94 Pharmaceuticals and Biotechnology stocks plotted is 18.89, with the middle half between 9.60 and 39.66.
The median is 13.3%, with the middle half between 4.8% and 35.0%.
The rank correlation (Spearman) is -0.04, a no meaningful negative relationship: knowing one tells you little about the other.
A company whose value lies more than three interquartile ranges beyond the first or third quartile is treated as an outlier. By default it stays on the chart, pinned to the edge as an open marker, and its true value is shown in the tooltip and the table. In this view 11 companies are outliers on Revenue Growth (1y) (TTM) and 5 on P/E. You can switch to percentile clamping, exclude outliers, or plot raw values on a log scale.
Metrics from Business Quant's screener: trailing-twelve-month figures from SEC filings and multiples on the latest close. A company appears once even when it lists more than one share class. A company with a secondary business line in this industry group is included unless you choose primary industry only. Nothing on this page is investment advice.